Lunning and Maddocks Talk Through Frontline MCL Management

Dr Lunning sits down with Kami J. Maddocks, MD, of The Ohio State University Comprehensive Cancer Center––James, to discuss the management of MCL in the up-front setting, including practice-changing findings from the SHINE and TRIANGLE trials; how these trial data have altered the role of first-line BTK inhibitors in chemotherapy-free regimens for patients with MCL; and how patient characteristics, such as age and TP53 mutation status affect up-front treatment feasibility.